Clinical Trials Logo

Phenylketonuria (PKU) clinical trials

View clinical trials related to Phenylketonuria (PKU).

Filter by:

NCT ID: NCT01889862 Completed - Clinical trials for Phenylketonuria (PKU)

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

Prism-2
Start date: July 29, 2013
Phase: Phase 3
Study type: Interventional

The BMN 165 clinical development program has been designed to demonstrate the safety and efficacy of BMN 165 in reducing blood Phe concentrations in adults with PKU.

NCT ID: NCT01806051 Terminated - Clinical trials for Phenylketonuria (PKU)

A Pilot Study on Diurnal Variation

Start date: March 2013
Phase: N/A
Study type: Interventional

This self-controlled, prospective, pilot study is designed to gather information regarding the diurnal variation (changes that occur each day) in the levels of plasma phenylalanine (Phe) and tyrosine in patients with phenylketonuria (PKU) and in the non-PKU population.

NCT ID: NCT01617070 Completed - Clinical trials for Phenylketonuria (PKU)

Effects of Kuvan on Melatonin Secretion

Start date: May 2012
Phase: Phase 4
Study type: Interventional

This study examines the effect of tetrahydrobiopterin (Kuvan) and Large Neutral Amino Acid (LNAA) therapy on melatonin and dopamine levels in individuals with Phenylketonuria (PKU). The investigators hypothesize that Kuvan therapy will improve melatonin secretion and urine dopamine levels to some extent. However significantly greater responses in melatonin and dopamine secretions may be observed with combined treatment with Kuvan and supplementation of LNAA.